The global fingolimod market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market is the increasing prevalence of multiple sclerosis disease. According to Atlas of MS, there are around 2.8 million people worldwide who are suffering from multiple sclerosis. This factor will fuel the demand of the market during the forecast period as fingolimod is used for the treatment of multiple sclerosis.

Fingolimod is an immunomodulation medication that is sold under the name of Gilenya. The drug was developed by Novartis and got approved by US FDA in 2010. The drug prevents immune system cells or also called lymphocytes from attacking the nerves present in your brain and spinal cord which can further prevent or delay the episodes which patients suffer, thus this major factor can lead to growing demand during the forecast period. Recently, in June 2021, Dr Reddy’s Laboratories got the US FDA approval to market the Fingolimod capsules which will be having a strength of 0.25 mg. The drug will be manufacture in the Ahmedabad factory of the company. Some of the key global players in the global fingolimod market include Novartis AG, AstraZeneca, Dr Reddy’s Laboratories, and many others.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Types

o By Application

• Competitive Landscape - Novartis AG, AstraZeneca, Dr Reddy’s Laboratories

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global fingolimod Market by Segments

By Type

• Oral 
• Injection

By Application

• Scientific Research
• Hospitals
• Others

Global fingolimod Market by Region